Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | CDC25C | P30307 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035236 | 0.78 | CDC25A (0.33) | CDC25ACDC25BCDC25C | |
| SCHEMBL13783751 | 0.63 | LMNA (0.44) | PARP1BRD4CREBBP | |
| SCHEMBL15253494 | 0.63 | AKR1B1 (0.38) | PARP1BRD4CREBBP | |
| SCHEMBL8190136 | 0.63 | PTGDR2 (0.36) | CDC25ACDC25BCDC25C | |
| SCHEMBL18186976 | 0.62 | KEAP1 (0.50) | PARP1BRD4CREBBPKCNH2HRH3 | |
| SCHEMBL16831977 | 0.62 | KEAP1 (0.50) | PARP1BRD4CREBBPKCNH2HRH3 | |
| SCHEMBL16831976 | 0.62 | KEAP1 (0.50) | PARP1BRD4CREBBPKCNH2HRH3 | |
| SCHEMBL10353380 | 0.62 | DNMT3B (0.40) | PARP1BRD4CREBBP | |
| SCHEMBL27827911 | 0.61 | AKR1B1 (0.37) | PARP1BRD4CREBBP | |
| SCHEMBL15041796 | 0.59 | ALDH1A1 (0.38) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PARP1 420/4885CDC25A 399/4885CDC25B 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.